Darrin R. Uecker serves as President, Chief Executive Officer, Director of the Company. Mr. Uecker has over 25 years of experience in the medical device field. From January 2014 to September 2015, Mr. Uecker was the President and Chief Operating Officer of Progyny, Inc., a company that developed EevaTM, the world’s first automated time-lapse system for embryo selection during in-vitro fertilization. From June 2009 to January 2014, Mr. Uecker was the Chief Executive Officer, and President and a Director of Gynesonics, Inc., a company that developed a novel medical device for the treatment of symptomatic uterine fibroids using ultrasound guided radiofrequency ablation. Prior to that, Mr. Uecker served in a variety of executive level roles, including as a Senior Vice President at CyperHeart, Inc. (June 2008 to June 2009), a company that developed an external beam radiation platform for the treatment of heart arrhythmias, a Senior Vice President at Conceptus, Inc. (May 2007 to June 2008), and as Chief Technology Officer at RITA Medical Systems, Inc. (January 2004 to January 2007), a medical device oncology company focused on ablative therapies. Mr. Uecker holds a M.S. degree in Electrical and Computer Engineering from the University of California at Santa Barbara.
As the President, Chief Executive Officer, and Director of Pulse Biosciences Inc, the total compensation of Darrin Uecker at Pulse Biosciences Inc is $1,420,300. There are 1 executives at Pulse Biosciences Inc getting paid more, with Sandra Gardiner having the highest compensation of $2,097,570.
Darrin Uecker is 54, he's been the President, Chief Executive Officer, and Director of Pulse Biosciences Inc since 2015. There are 8 older and 2 younger executives at Pulse Biosciences Inc. The oldest executive at Pulse Biosciences Inc is Robert Duggan, 75, who is the Independent Chairman of the Board.
Darrin's mailing address filed with the SEC is C/O PULSE BIOSCIENCES, INC., 3957 POINT EDEN WAY, HAYWARD, CA, 94545.
Over the last 8 years, insiders at Pulse Biosciences Inc have traded over $0 worth of Pulse Biosciences Inc stock and bought 18,070,761 units worth $194,618,110 . The most active insiders traders include Robert W Duggan, Mahkam Zanganeh, and Manmeet Singh Soni. On average, Pulse Biosciences Inc executives and independent directors trade stock every 52 days with the average trade being worth of $6,179,107. The most recent stock trade was executed by Burke Thomas Barrett on 20 May 2024, trading 10,000 units of PLSE stock currently worth $85,600.
pulse biosciences, inc. is a clinical stage electroceutical, an electrical energy based therapeutic, company pursuing commercial applications of its proprietary nano-pulse stimulation (nps) technology. nps is a non-thermal, drug-free energy-based technology that can stimulate unique behaviors in cells by applying ultra-short nanosecond (billionths of a second) electrical pulses that affect the cell membrane and intracellular structures. these cell effects influence cell regulation functions and can lead to unique immune system responses. pulse biosciences is investigating a variety of applications for its nps technology that exploits its unique biologic effect, including immuno-oncology and dermatology. pulse biosciences, inc. (plse, nasdaq) corporate headquarters is located in hayward, ca. ~ our mission ~ to build a viable company that designs, produces, and commercializes nano-pulse technology to improve and extend the lives of patients to solve the needs of patients, physicians, and
Pulse Biosciences Inc executives and other stock owners filed with the SEC include: